Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2704 - Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Gastrointestinal Cancers


Li-Tzong Chen


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


L. Chen1, T.M. Macarulla2, J. Blanc3, B. Mirakhur4, F.A. de Jong5, B. Belanger6, T. Bekaii-Saab7, J. Siveke8

Author affiliations

  • 1 Internal Medicine, National Health Research Institutes – National Institute of Cancer Research, 350 - Tainan/TW
  • 2 Vall D'hebron Institute Of Oncology (vhio), Vall d'Hebron University Hospital (HUVH), Barcelona/ES
  • 3 Chu Bordeaux, Groupe Hospitalier Hau-Lévêque, Pessac/FR
  • 4 Medical Affairs, Ipsen Biopharmaceuticals,Inc., Basking Ridge/US
  • 5 Medical Affairs, Shire GmbH, ZUG/CH
  • 6 Biometry R&d, Ipsen Biopharmaceuticals,Inc., Basking Ridge/US
  • 7 Internal Medicine, Division of Hematology/Medical Oncology, Mayo Clinic, Phoenix/US
  • 8 Division Of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen/DE

Abstract 2704


Chemotherapy dose modifications to manage adverse events (AEs) is common in clinical practice. In NAPOLI-1 (NCT01494506), a randomized phase 3 study in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy, nal-IRI+5-FU/LV improved overall survival (OS; primary endpoint) vs 5-FU/LV (6.1 mos vs 4.2 mos; HR = 0·67, 95% CI 0.49–0.92; P = 0.012). The study protocol permitted dose modifications (reduction or delay) to address toxicity. In this exploratory post-hoc analysis, we evaluated the impact of nalIRI dose modifications on overall survival (OS) and progression-free survival (PFS).


All pts enrolled under protocol v2 who received nal-IRI+5-FU/LV during the first 6 wks were included in the analysis. Pts were grouped according to those with dose modification or those without dose modification. Dose reduction was defined as any decrease from initial dose, delay as any dosing delay >3 days from target date. Pts without dose modification received the first 3 scheduled doses of nal-IRI+5-FU/LV without qualifying delay/reduction. OS and PFS (KaplanMeier estimates) were compared within the nal-IRI+5-FU/LV arm. Unstratified hazard ratios (HRs) were calculated using Cox regression.


Among pts in the nal-IRI+5-FU/LV arm (n = 93), 40 pts had no dose modification and 53 had a dose modification (delay, n = 49; reduction, n = 34). Within the nal-IRI+5-FU/LV arm, there was no significant difference in median OS or PFS between pts with vs without dose modification (Table).


Dose modification of nal-IRI+5-FU/LV in the first 6 wks does not significantly impact OS or PFS compared to patients without dose modifications. This suggests that tolerability-guided dose modification of nal-IRI does not adversely affect efficacy outcomes.Table: 734P

Median OSMedian PFS
Pts (n)MonthsHR (95% CI)Pts (n)MonthsHR (95% CI)
nal-IRI+5-FU/LV Delay498.41.10 (0.71, 1.70)494.21.03 (0.66, 1.61)
nal-IRI+5-FU/LV No delay438.3434.0
nal-IRI+5-FU/LV Reduction349.40.87 (0.54, 1.39)344.20.91 (0.56, 1.48)
nal-IRI+5-FU/LV No reduction488.4484.1

Clinical trial identification


Legal entity responsible for the study

Ipsen Biopharmaceuticals, Inc.


Ipsen Biopharmaceuticals, Inc.

Editorial Acknowledgement

Editorial assistance for the abstract was provided by The Medicine Group (New Hope, PA); Philip Sjostedt, BPharm; Susan Martin, PhD.


L-T. Chen: Consulting, Advisory role: Bristol-Myers Squibb, Five Prime Therapeutics, Lilly, Merrimack, MSD, Novartis, Ono Pharmaceutical, PharmaEngine, Syncope, Taiwan, TTY Biopharm Research funding (Inst): GlaxoSmithKline, Merck Serono, Novartis, Polaris, TTY Biopharm, Patents, Royalties, Other intellectual property: Anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan. J. Blanc: Honoraria: Baxalta/Shire, Bayer Schering Pharma, Gilead Sciences; Consulting, Advisory role: Baxalta/Shire, Bristol-Myers Squibb, Novartis, Onxeo; Travel, accommodations, expenses: Bayer Schering Pharma. B. Mirakhur, B. Belanger: Employee, Stock and other ownership interests: Ipsen Biopharmaceuticals, Inc. F.A. de Jong: Employee: Shire; Stock and other ownership interests: Amgen, Shire. T. Bekaii-Saab: Consulting, Advisory role: Amgen, Bayer, Boehringer Ingelheim, Celgene, Genentech/Roche, Glenmark, Lilly, Merrimack, NCCN, Pfizer, Research to practice, Sirtex Medical, Taiho Pharmaceutical; Other relationship: Exelixis, Merck, Polaris. J. Siveke: Consulting, advisory role: Baxalta, Celgene, Lilly, Merrimack Research funding: 4SC, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Novartis; Travel, accommodations, expenses: Celgene, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.